High-molecular-weight kininogen and the intrinsic coagulation pathway in patients with de novo acute myocardial infarction

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1121-1134

  Cubedo, Judit ^a,b   Ramaiola, Ilaria ^a,b   Padró, Teresa ^a,b   Martin Yuste, Victoria ^d   Sabate Tenas, Manel ^d   Badimon, Lina ^a,b,c  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute myocardial infarction; Fibrinogen; High molecular weight kininogen; Proteomics; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 11; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BIOINFORMATICS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE NECROSIS; HUMAN; ISCHEMIA; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; THROMBECTOMY; THROMBUS ASPIRATION;

ACUTE MYOCARDIAL INFARCTION; FIBRINOGEN; HIGH-MOLECULAR WEIGHT KININOGEN; PROTEOMICS; THROMBUS;

ACUTE DISEASE; AGED; BLOOD COAGULATION; COMPUTATIONAL BIOLOGY; FACTOR XI; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84888418179     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0381     Document Type: Article

References (39)

1. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.
2. Moyssakis I, Vlahodimitris IE, Kanakis MA, et al. Behavior of coagulation factors and normal inhibitors of coagulation during the acute phase of myocardial infarction. Blood Coagul Fibrinolysis 2010; 21: 670-673.
3. Ko YG, Jung JH, Park S, et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol 2006; 112: 66-71.
4. Lippi G, Filippozzi L, Montagnana M, et al. Diagnostic value of D-dimer measurement in patients referred to the emergency department with suspected myocardial ischaemia. J Thromb Thrombolysis 2008; 25: 247-250.
5. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-1787.
6. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
7. Gailani D, Broze GJ. Factor XI and the contact system. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill, 2001; pp. 4433.
8. Siegerink B, Rosendaal FR, Algra A. High molecular weight kininogen and the risk of myocardial infarction and ischaemic stroke in young women: the ratio case-control study. J Thromb Haemost 2012; Epub ahead of print doi: 10.1111/j. 1538-7836. 2012. 04927. x.
9. Arab S, Gramolini AO, Ping P, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006; 48: 1733-1741.
10. Cubedo J, Padró T, García-Moll X, et al. Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res 2011; 10: 211-220.
11. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction Lancet 2001; 357: 21-28.
12. Cubedo J, Padró T, Alonso R, et al. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis 2012; 222: 263-269.
13. Shand JA, Menown IB, McEneaney DJ. A timely diagnosis of myocardial infarction. Biomark Med 2010; 4: 385-393.
14. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-2327.
15. Bayes-Genis A, Mateo J, Santaló M, et al. D-Dimer is an early diagnostic marker of coronary ischaemia in patients with chest pain. Am Heart J 2000; 140: 379-384.
16. Mauron T, Lämmle B, Wuillemin WA. High molecular weight kininogen is cleaved by FXIa at three sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. Thromb Haemost 2000; 83: 709-714.
17. Lalmanach G, Naudin C, Lecaille F, et al. Kininogens: More than cysteine protease inhibitors and kinin precursors. Biochimie 2010; 92: 1568-1579.
18. Tanaka M, Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. Thromb Res 1994; 76: 289-298.
19. Vaziri ND, Kennedy SC, Kennedy D, et al. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93: 651-657.
20. Mateos-Cáceres PJ, García-Méndez A, López Farré A, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004; 44: 1578-1583.
21. Collet JP, Nagaswami C, Farrell DH, et al. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004; 24: 382-386.
22. van der Putte RF, Glatz JF, Hermens WT. Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. Clin Chim Acta 2006; 371: 37-54.
23. Hunt FA, Rylatt DB, Hart RA, et al. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol 1985; 60: 715-722.
24. Lee LV, Ewald GA, McKenzie CR, et al. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 628-633.
25. Gurfinkel E, Bozovich G, Cerdá M, et al. Time significance of acute thrombotic reactant markers in patients with and without silent myocardial ischaemia and overt unstable angina pectoris. Am J Cardiol 1995; 76: 121-124.
26. Ieko M, Naito S, Yoshida M, et al. Plasma soluble fibrin monomer complex as a marker of coronary thrombotic events in patients with acute myocardial infarction. Tohoku J Exp Med 2009; 219: 25-31.
27. Orak M, Ustündag M, Güloglu C, et al. The role of serum D-dimer level in the diagnosis of patients admitted to the emergency department complaining of chest pain. J Int Med Res 2010; 38: 1772-1779.
28. Saigo M, Hsue PY, Waters DD. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 2004; 46: 524-538.
29. Guzzetta NA, Miller BE, Todd K, et al. Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg 2006; 103: 1131-1138.
30. Hoogendoorn H, Toh CH, Nesheim ME, et al. Alpha 2-macroglobulin binds and inhibits activated protein C. Blood 1991; 78: 2283-2290.
31. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-145.
32. Crook M, Haq M, Haq S, et al. Plasma sialic acid and acute-phase proteins in patients with myocardial infarction. Angiology 1994; 45: 709-715.
33. Mori T, Sasaki J, Kawaguchi H, et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995; 129: 234-238.
34. Lee C, Bongcam-Rudloff E, Sollner C, et al. Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front Biosci 2009; 14: 2911-2922.
35. Poon IK, Olsson AK, Hulett MD, et al. Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage. Biochem J 2009; 424: 27-37.
36. Vu TT, Stafford AR, Leslie BA, et al. Histidine-rich glycoprotein binds fibrin (ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem 2011; 286: 30314-30323.
37. Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77: 1305-1311.
38. Lijnen HR, Van Hoef B, Collen D. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb Haemost 1984; 51: 266-268.
39. Lijnen HR, van Hoef B, Collen D. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III. Thromb Haemost 1983; 50: 560-562.